0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Determination by Anti-Bromodeoxyuridine Monoclonal Antibody of Cells in S Phase in the Human Y79 Retinoblastoma Line Maintained in an Organ Culture System: Effects of Butyric Acid

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Using bromodeoxyuridine (BrdU) and an anti-BrdU monoclonal antibody (Mab), the fraction of cells in S phase of the Y79 human retinoblastoma line maintained in an organ culture system was determined. The average labeling index (LI) (S phase cell fraction) was 21.5% after 2–15 days in vitro. The effect of butyric acid, which has been reported by others to inhibit the growth of Y79 retinoblastoma cells, was then evaluated in a similar in vitro system. Following treatment with 2 and 3 m M of butyric acid, extensive necrosis was seen in the cultures, and the LI of the surviving cells was significantly (p < 0.01) lower (4.1 and 2.9%, respectively) than that of the control cultures (21.1%). Forty-eight hours after removal of butyric acid, the LI of the cultures treated respectively with 2 and 3 m M of butyric acid returned to the control level. Our findings suggest that the effect of butyric acid on the cell kinetics of Y79 retinoblastoma cells may be a reversible blocking effect on the G<sub>1</sub> phase of the cell cycle.

          Related collections

          Author and article information

          Journal
          ORE
          Ophthalmic Res
          10.1159/issn.0030-3747
          Ophthalmic Research
          S. Karger AG
          0030-3747
          1423-0259
          1987
          1987
          04 December 2009
          : 19
          : 4
          : 205-212
          Affiliations
          Division of Neuropathology, Department of Pathology, University of Virginia School of Medicine, Charlottesville, Va., USA
          Article
          265495 Ophthalmic Res 1987;19:205–212
          10.1159/000265495
          3696696
          © 1987 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 8
          Categories
          Original Paper

          Comments

          Comment on this article